Krzywoń Lucyna, Lazaris Anthoula, Petrillo Stephanie K, Zlotnik Oran, Gao Zu-Hua, Metrakos Peter
Cancer Research Program, Research Institute of McGill University Health Center Glen Site, McGill University Health Center, Royal Victoria Hospital-Glen Site, 1001 Decarie Blvd Room E02.6218, Montreal, QC H4A 3J1, Canada.
Department of Experimental Surgery, McGill University, 1650 Cedar Ave., Room A7.117, Montreal, QC H4A 3J1, Canada.
Cancers (Basel). 2024 Sep 13;16(18):3148. doi: 10.3390/cancers16183148.
Colorectal cancer liver metastasis (CRCLM) remains a lethal diagnosis, with an overall 5-year survival rate of 5-10%. Two distinct histopathological growth patterns (HGPs) of CRCLM are known to have significantly differing rates of patient survival and response to treatment. We set out to review the results of 275 patients who underwent liver resection for CRCLM at the McGill University Health Center (MUHC) and analyze their clinical outcome, mutational burden, and pattern of cancer progression in light of their HGPs, and to consider their potential effect on surgical decision making.
We performed a retrospective multivariate analysis on clinical data from patients with CRCLM ( = 275) who underwent liver resection at the McGill University Health Center (MUHC). All tumors were scored using international consensus guidelines by pathologists trained in HGP scoring.
A total of 109 patients (42.2%) were classified as desmoplastic and angiogenic, whereas 149 patients (57.7%) were non-desmoplastic and vessel co-opting. The 5-year survival rates for angiogenic patients compared with vessel co-opting patients were 47.1% and 13%, respectively ( < 0.0001). Multivariate analysis showed patients with vessel co-opting CRCLM had a higher incidence of extrahepatic metastatic disease ( = 0.0215) compared with angiogenic CRCLM. Additionally, KRAS mutation status was a marker of increased likelihood of disease recurrence ( = 0.0434), as was increased number of liver tumors ( = 0.0071) and multiple sites of extrahepatic metastatic disease ( < 0.0001).
Multivariate analysis identified key clinical prognostic and molecular features correlating with the two HGPs. Determining liver tumor HGPs is essential for patient prognostication and treatment optimization.
结直肠癌肝转移(CRCLM)仍然是一种致命的诊断,总体5年生存率为5%-10%。已知CRCLM的两种不同组织病理学生长模式(HGPs)患者的生存率和对治疗的反应率存在显著差异。我们着手回顾在麦吉尔大学健康中心(MUHC)接受CRCLM肝切除术的275例患者的结果,并根据其HGPs分析他们的临床结局、突变负荷和癌症进展模式,并考虑其对手术决策的潜在影响。
我们对在麦吉尔大学健康中心(MUHC)接受肝切除术的CRCLM患者(n = 275)的临床数据进行了回顾性多变量分析。所有肿瘤均由经过HGP评分培训的病理学家按照国际共识指南进行评分。
共有109例患者(42.2%)被分类为促结缔组织增生性和血管生成性,而149例患者(57.7%)为非促结缔组织增生性和血管共生性。血管生成性患者与血管共生性患者的5年生存率分别为47.1%和13%(P < 0.0001)。多变量分析显示,与血管生成性CRCLM相比,血管共生性CRCLM患者肝外转移疾病的发生率更高(P = 0.0215)。此外,KRAS突变状态是疾病复发可能性增加的一个标志物(P = 0.0434),肝肿瘤数量增加(P = 0.0071)和肝外转移疾病的多个部位也是如此(P < 0.0001)。
多变量分析确定了与两种HGPs相关的关键临床预后和分子特征。确定肝肿瘤HGPs对于患者预后评估和治疗优化至关重要。